WEALTH ENHANCEMENT ADVISORY SERVICES, LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 1632972
PLYMOUTH, MN
Position in DNLI
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$423,531
New position
Shares Held
16,467
first reported quarter
Ownership
0.010%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#158
of 290 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 4%
Shared 0%
None 96%
Position in Biotechnology
Healthcare · as of Jun 30, 2026WEALTH ENHANCEMENT ADVISORY SERVICES, LLC holds $166,117,226 across 147 Biotechnology names. DNLI ranks #55 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
45,889 | $22,794,442 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
33,880 | $21,125,535 | |
| 3 | INCY |
Incyte Corp
|
151,505 | $17,174,606 | |
| 4 | EXEL |
Exelixis, Inc.
|
207,728 | $11,302,480 | |
| 5 | RPRX |
Royalty Pharma plc
|
179,888 | $10,086,320 | |
| 6 | CORT |
Corcept Therapeutics Inc
|
76,278 | $6,632,372 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
70,797 | $5,541,281 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
19,919 | $4,875,573 |
All Filings in DNLI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $423,531 | 16,467 | Shares | Sole | 2026-07-15 | |
| No filing history on record for this holder in this stock. | ||||||